0 results for 'Foley Lardner'
Behind the Scenes: Lobbying Battles of 2001
Lobbying, a unique hybrid of government, law and business, compels us to measure success differently. Great lobbying campaigns can have any of a number of outcomes, many often shaded in gray. What matters is how the game is played. Here is a particular angle on 10 of the most important issues before Congress in 2001, a rundown of the players and a nifty illustration of the old maxim "politics makes strange bedfellows."Federal Prosecutor Leading Apple Probe to Leave for Fenwick
Christopher Steskal, the federal prosecutor leading a criminal probe into Apple's options grants, will leave the San Francisco U.S. Attorney's Office next month to head Fenwick & West's white-collar practice. Also the lone prosecutor in the Brocade backdating case, Steskal has been especially busy of late -- Apple CEO Steve Jobs was interviewed by prosecutors and SEC lawyers last week, according to sources. Dozens of options cases are now in limbo, with U.S. Attorney Kevin Ryan on his way out as well.Ambac and its fellow bond insurer MBIA went hard at banks, accusing them of fraudulently obtaining insurance policies on subprime-backed securities. But so far, the litigation doesn't seem to have been a smashing success for the insurers.
Perseverance Gets Genentech Back to Agensys' Table
In 2002 Alan Mendelson, of Latham & Watkins, ensured that Agensys Inc. had enough property and cash to put together a private placement that brought in $42 million. And Agensys' IP portfolio was strong enough to attract biotech giant Genentech Inc.'s attention. Two years before the funding came in, Agensys had signed a $30 million licensing deal with Genentech. Agensys' future looked bright -- but then the Genentech deal tanked.Tech Circuit: Mayan Year 5,126 Edition
The legal technology community predicts unexpected trends for 2013, including changes in e-discovery, cloud computing, and information governance. [MORE]Upcoming Trial Highlights Disclosure Requirements of Biotech Companies
In a civil fraud action set for a May trial, the SEC argues that Biopure, its GC Jane Kober and two former executives misled investors about the prospects for Hemopure, a blood substitute that is the company's flagship product. The outcome will provide important guidance to other biotechnology outfits, particularly those built around a single product. One major issue in the case is an undeniably upbeat Biopure press release that came after the FDA suspended review of Hemopure pending more information.Games Lawyers Play: Backdating Edition
We compare the recently exposed Mercury complaint to the reasons Orrick and Shearman gave to keep it hidden. No Subscription RequiredTrending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
The Essential Guide to Governance, Risk, and Compliance
Brought to you by Diligent Corporation
Download Now
2024 Trends Report Mid-Year Special Edition: Update on Outside Counsel Billing Rates
Brought to you by LexisNexis® CounselLink®
Download Now
AI in Private Equity: A Guide for Gaining an Early Advantage
Brought to you by Ontra
Download Now
Why Are So Many Law Firms Suddenly Embracing Digital Transformation?
Brought to you by AllRize
Download Now